Advertisement

Molecular Biology Reports

, Volume 38, Issue 8, pp 5443–5448 | Cite as

Study the polymorphism of CYP3A5 and CYP3A4 loci in Iranian population with laryngeal squamous cell carcinoma

  • Negar Azarpira
  • Mohamad Javad Ashraf
  • Bigan Khademi
  • Masumeh Darai
  • Afsoon Hakimzadeh
  • Elham Abedi
Article

Abstract

Cancer reflects a complicated network of interactions between genes and environmental factors. Cytochrome P450 (CYP) is a multi-gene superfamily participating in the metabolism of xenobiotics. The aim of our study was to examine whether polymorphisms in the CYP enzyme genes affect the risk of developing larynx squamous cell carcinoma (SCC). Polymorphism of CYP3A5 and CYP3A4 genes were investigated in 50 patients with laryngeal SCC and 100 control subjects by polymerase chain reaction- restriction fragment length polymorphism (PCR-RFLP). In patients the CYP3A5 3*/3* and 1*/3*genotypes were detected in 92% and 8% respectively. There was no relation between genotype, allele frequency and grade/stage of tumor. In control group, the frequency of CYP3A5 3*/3* and CYP3A5 1*/3* genotype were 98% and 2% respectively. There was no significant difference in genotype and allele frequency of this gene between patient and control group. In respect of CYP3A41A*/B*, people in both patient and control groups had the same genotype of CYP3A41A*/1A*. In this study, the CYP gene variants were not associated with increased risk of laryngeal SCC. Study on the other genetic factors which are involved in activation/detoxication of procarcinogenes, such as CYP1A1, CYP1B1, CYP2E1 and gluthation S transferase is recommended.

Keywords

Squamous cell carcinoma Larynx CYP3A5 CYP3A4 Polymorphisms 

References

  1. 1.
    Sankaranarayanan R, Masuyer E, Swaminathan R, Ferlay J, Whelan S (1998) Head and neck cancer: a global perspective on epidemiology and prognosis. Anticancer Res 18(6B):4779–4786PubMedGoogle Scholar
  2. 2.
    Rutt AL, Hawkshaw MJ, Sataloff RT (2010) Laryngeal cancer in patients younger than 30 years: a review of 99 cases. Ear Nose Throat J 89(4):189–192PubMedGoogle Scholar
  3. 3.
    Ashraf MJ, Maghbul M, Azarpira N, Khademi B (2010) Expression of Ki67 and P53 in primary squamous cell carcinoma of the larynx. Indian J Pathol Microbiol 53(4):661–665PubMedCrossRefGoogle Scholar
  4. 4.
    Nelson DR, Koymans L, Kamataki T et al (1996) P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6(1):1–42PubMedCrossRefGoogle Scholar
  5. 5.
    Patten CJ, Smith TJ, Friesen MJ, Tynes RE, Yang CS, Murphy SE (1997) Evidence for cytochrome P450 2A6 and 3A4 as major catalysts for N0-nitrosonornicotine a-hydroxylation by human liver microsomes. Carcinogenesis 18(8):1623–1630PubMedCrossRefGoogle Scholar
  6. 6.
    Gonzalez FJ (1997) The role of carcinogen-metabolizing enzyme polymorphisms in cancer susceptibility. Reprod Toxicol 11(2–3):397–412PubMedCrossRefGoogle Scholar
  7. 7.
    Wenzlaff AS, Cote ML, Bock CH, Land SJ, Santer SK, Schwartz DR, Schwartz AG (2005) CYP1A1 and CYP1B1 polymorphisms and risk of lung cancer among never smokers: a population-based study. Carcinogenesis 26(12):2207–2212PubMedCrossRefGoogle Scholar
  8. 8.
    Abdel-Rahman SZ, Anwar WA, Abdel-Aal WE, Ghoneim MA, Au WW (1997) The CYP2D6 extensive metabolizer genotype is associated with increased risk for bladder cancer. Cancer Lett 119(1):115–122PubMedCrossRefGoogle Scholar
  9. 9.
    Sergentanis TN, Economopoulos KP, Choussein S, Vlahos NF (2011) Cytochrome P450 1A1 gene polymorphisms and endometrial cancer risk: a meta-analysis. Int J Gynecol Cancer 21(2):323–331PubMedCrossRefGoogle Scholar
  10. 10.
    Souiden Y, Mahdouani M, Chaieb K, Elkamel R, Mahdouani K (2010) CYP17 gene polymorphism and prostate cancer susceptibility in a Tunisian population. Cancer Epidemiol. doi: 10.1016/j.canep.2010.11.008
  11. 11.
    Pavanello S, B’chir F, Pulliero A, Saguem S, Ben Fraj R, El Aziz Hayouni A, Clonfero E, Mastrangelo G (2007) Interaction between CYP1A2–T2467DELT polymorphism and smoking in adenocarcinoma and squamous cell carcinoma of the lung. Lung Cancer 57(3):266–272PubMedCrossRefGoogle Scholar
  12. 12.
    Varzim G, Monteiro E, Silva RA, Fernandes J, Lopes C (2003) CYP1A1 and XRCC1 gene polymorphisms in SCC of the larynx. Eur J Cancer Prev 12(6):495–499PubMedCrossRefGoogle Scholar
  13. 13.
    Ko Y, Abel J, Harth V, Bröde P, Antony C, Donat S, Fischer HP, Ortiz-Pallardo ME, Thier R, Sachinidis A, Vetter H, Bolt HM, Herberhold C, Brüning T (2001) Association of CYP1B1 codon 432 mutant allele in head and neck squamous cell cancer is reflected by somatic mutations of p53 in tumor tissue. Cancer Res 61(11):4398–4404Google Scholar
  14. 14.
    Singh AP, Shah PP, Mathur N, Buters JT, Pant MC, Parmar D (2008) Genetic polymorphisms in cytochrome P4501B1 and susceptibility to head and neck cancer. Mutat Res 639(1–2):11–19PubMedGoogle Scholar
  15. 15.
    Neuhaus T, Ko YD, Lorenzen K, Fronhoffs S, Harth V, Brode P, Vetter H, Bolt HM, Pesch B, Bruning T (2004) Association of cytochrome P450 2E1 polymorphisms and head and neck squamous cell cancer. Toxicol Lett 151(1):273–282Google Scholar
  16. 16.
    Tai J, Yang M, Ni X, Yu D, Fang J, Tan W, Huang Z, Wu C, Chen X, Wang G, Zhou W, Chen X, Zhang W, Ma L, Lin D, Han D (2010) Genetic polymorphisms in cytochrome P450 genes are associated with an increased risk of squamous cell carcinoma of the larynx and hypopharynx in a Chinese population. Cancer Genet Cytogenet 196(1):76–82PubMedCrossRefGoogle Scholar
  17. 17.
    Gajecka M, Rydzanicz M, Jaskula-Sztul R, Kujawski M, Szyfter W, Szyfter K (2005) CYP1A1, CYP2D6, CYP2E1, NAT2, GSTM1 and GSTT1 polymorphisms or their combinations are associated with the increased risk of the laryngeal squamous cell carcinoma. Mutat Res 574(1–2):112–123PubMedGoogle Scholar
  18. 18.
    Tsuchiya N, Satoh S, Tada H, Li Z, Ohyama C, Sato K, Suzuki T, Habuchi T, Kato T (2004) Influence of CYP3A5 and MDR1 polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation 78(8):1182–1187PubMedCrossRefGoogle Scholar
  19. 19.
    Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, Nuessler AC, Neuhaus P, Klattig J, Eiselt R, Koch I, Zibat A, Brockmöller J, Halpert JR, Zanger UM, Wojnowski L (2001) The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11(9):773–779PubMedCrossRefGoogle Scholar
  20. 20.
    Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27(4):383–391PubMedCrossRefGoogle Scholar
  21. 21.
    Raucy JL (2003) Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. Drug Metab Dispos 31(5):533–539PubMedCrossRefGoogle Scholar
  22. 22.
    Kadlubar FF, Berkowitz GS, Delongchamp RR, Wang C, Green BL, Tang G, Lamba J, Schuetz E, Wolff MS (2003) The CYP3A4*1B variant is related to the onset of puberty, a known risk factor for the development of breast cancer. Cancer Epidemiol Biomarkers Prev 12(4):327–331PubMedGoogle Scholar
  23. 23.
    Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, Morrow M (eds) (2002) American Joint Committee on Cancer; American Cancer Society. American Joint Committee on Cancer staging manual, 6th edn. Springer, PhiladelphiaGoogle Scholar
  24. 24.
    Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E, Sobin LH (eds) (1999) Histological typing of lung and pleural tumors, 3rd edn. World Health Organization. World Health Organization International Histological Classification of Tumours, GenevaGoogle Scholar
  25. 25.
    Gonzales FJ (1992) Human cytochrome P450: problems and prospects. Trends Pharmacol Sci 13(9):346–352Google Scholar
  26. 26.
    Sarikaya D, Bilgen C, Kamataki T, Topcu Z (2006) Comparative cytochrome P450 −1A1, −2A6, −2B6, −2C, −2D6, −2E1, −3A5 and −4B1 expressions in human larynx tissue analysed at mRNA level. Biopharm Drug Dispos 27(8):353–359PubMedCrossRefGoogle Scholar
  27. 27.
    Lacko M, Oude Ophuis MB, Peters WH, Manni JJ (2009) Genetic polymorphisms of smoking-related carcinogen detoxifying enzymes and head and neck cancer susceptibility. Anticancer Res 29(2):753–761PubMedGoogle Scholar
  28. 28.
    Sharifi R, Allameh A, Biramijamal F, Mohammadzadeh SH, Rasmi Y, Tavangar SM, Jamali-Zavarei M (2008) Relationship between genetic polymorphism of glutathione S-transferase-p1 and p53 protein accumulation in Iranian esophageal squamous cell carcinoma patients. Indian J Cancer 45(1):8–12PubMedCrossRefGoogle Scholar
  29. 29.
    Sun L, König IR, Homann N (2009) Manganese superoxide dismutase (MnSOD) polymorphism, alcohol, cigarette smoking and risk of oesophageal cancer. Alcohol Alcohol 44(4):353–357PubMedGoogle Scholar
  30. 30.
    Tang K, Li Y, Zhang Z, Gu Y, Xiong Y, Feng G, He L, Qin S (2010) The PstI/RsaI and DraI polymorphisms of CYP2E1 and head and neck cancer risk: a meta-analysis based on 21 case–control studies. BMC Cancer 10:575PubMedCrossRefGoogle Scholar
  31. 31.
    Sabitha K, Reddy MV, Jamil K (2010) Smoking related risk involved in individuals carrying genetic variants of CYP1A1 gene in head and neck cancer. Cancer Epidemiol 34(5):587–592PubMedCrossRefGoogle Scholar
  32. 32.
    Unal ZN, Unal M, Bağdatoğlu OT, Polat G, Atik U (2008) Genetic polymorphism of VEGF-1154 (A/G) in laryngeal squamous cell carcinoma. Arch Med Res 39(2):209–211PubMedCrossRefGoogle Scholar
  33. 33.
    Khademi B, Razmkhah M, Erfani N, Gharagozloo M, Ghaderi A (2008) SDF-1 and CCR5 genes polymorphism in patients with head and neck cancer. Pathol Oncol Res 14(1):45–50PubMedCrossRefGoogle Scholar
  34. 34.
    Upadhyay R, Jain M, Kumar S, Ghoshal UC, Mittal B (2008) Association of interleukin-6 (−174G>C) promoter polymorphism with risk of squamous cell esophageal cancer and tumor location: an exploratory study. Clin Immunol 128(2):199–204PubMedCrossRefGoogle Scholar
  35. 35.
    Ruwali M, Parmar D (2010) Association of functionally important polymorphisms in cytochrome P450s with squamous cell carcinoma of head and neck. Indian J Exp Biol 48(7):651–665PubMedGoogle Scholar
  36. 36.
    Lu D, Yu X, Du Y (2010) Meta-analyses of the effect of cytochrome P450 2E1 gene polymorphism on the risk of head and neck cancer. Mol Biol Rep. doi: 10.1007/s11033-010-0375-9

Copyright information

© Springer Science+Business Media B.V. 2011

Authors and Affiliations

  • Negar Azarpira
    • 1
    • 2
  • Mohamad Javad Ashraf
    • 2
  • Bigan Khademi
    • 3
  • Masumeh Darai
    • 1
  • Afsoon Hakimzadeh
    • 2
  • Elham Abedi
    • 2
  1. 1.Organ Transplant Research CenterNemazi Hospital, Shiraz University of Medical SciencesShirazIran
  2. 2.Department of PathologyKhalili Hospital, Shiraz University of Medical SciencesShirazIran
  3. 3.Department of OtolaryngologyKhalili Hospital, Shiraz University of Medical SciencesShirazIran

Personalised recommendations